CI

At a glance

ClinicalIndex Comparison Record
Phase 3Completed· 200 enrolled
Drug / intervention
DSP-5423Pdrug
Likely dose
DSP-5423P 80mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT02335658
NCT02335658Phase 3Completed
CompareCT.gov

Long-term Study of DSP-5423P in Patients With Schizophrenia <Phase 3>

Sumitomo Pharma Co., Ltd.·interventional·Posted Jan 12, 2015·Updated Apr 12, 2022

In Brief

A Phase 3 clinical trial evaluating DSP-5423P for Schizophrenia. Completed, enrolled 200 participants across 1 site.

Detailed Summary

The study evaluates the long term safety of DSP-5423P in patients with schizophrenia.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsSchizophrenia
CountriesJapan
Collaborators--

Timeline

Phase 3CompletedFinished
201520162017201820192020202120222023202420252026
First PostedJan 12, 2015
Enrollment StartDec 1, 2014
Primary CompletionMay 1, 2017
TodayJul 2, 2026
Enrollment to primary: 2.4 yearsPosted 11.5 years ago

Interventions

DSP-5423Pdrug

40-80mg/day